<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg (Tehran)</journal-id><journal-id journal-id-type="iso-abbrev">Emerg (Tehran)</journal-id><journal-id journal-id-type="publisher-id">Emerg</journal-id><journal-title-group><journal-title>Emergency</journal-title></journal-title-group><issn pub-type="ppub">2345-4563</issn><issn pub-type="epub">2345-4571</issn><publisher><publisher-name>Shahid Beheshti University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26495385</article-id><article-id pub-id-type="pmc">4614594</article-id><article-id pub-id-type="publisher-id">emerg-3-70</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Comparison of Intravenous Metoclopramide and Acetaminophen in Primary Headaches: a Randomized Controlled Trial </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Faridaalaee</surname><given-names>Gholamreza</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rahmani</surname><given-names>Seyed Hesam</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mehryar</surname><given-names>Hamidreza</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bina Shishavan</surname><given-names>Shahab</given-names></name><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Merghati</surname><given-names>Seyedeh Zahra</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Valizade Hasanloei</surname><given-names>Mohammad Amin</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Naghipour</surname><given-names>Bahman</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rahmani</surname><given-names>Farzad</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Emergency Medicine, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, IR Iran.</aff><aff id="aff2"><label>2</label>Department of Internal Surgery, School of Nursing and Midwifery, International branch of Urmia University of Medical Sciences, Urmia, IR Iran.</aff><aff id="aff3"><label>3</label>Department of Anesthesiology, Urmia University of Medical Sciences, Urmia, IR Iran.</aff><aff id="aff4"><label>4</label>Department of Anesthesiology, Tabriz University of Medical Sciences, Tabriz, IR Iran.</aff><aff id="aff5"><label>5</label>Department of Emergency Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</aff><author-notes><corresp id="cor1"><label>*</label>Corresponding Author: Bina Shishavan Shahab, Department of Emergency Medicine, Imam Khomeini Hospital, Ershad Avenue, Urmia, Iran. Tel: +989141889486; Fax: +984433457286; Email: <email>shahabbina@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Spring</season><year>2015</year></pub-date><volume>3</volume><issue>2</issue><fpage>70</fpage><lpage>74</lpage><history><date date-type="received"><month>9</month><year>2014</year></date><date date-type="accepted"><month>11</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Shahid Beheshti University of Medical Sciences. All rights reserved.</copyright-statement><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0), (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>)which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><sec><title>Introduction:</title><p>Headache is the most common neurologic symptom among referees to the emergency department (ED), while the best treatment has not yet been found. Therefore, in the present study pain relief effects of metoclopramide and acetaminophen were compared in patients suffered acute primary headache. </p></sec><sec><title>Methods:</title><p> This study was a double-blind randomized clinical trial performed in Imam Khomeini Hospital, Urmia, Iran, through July to October 2014. All adult patients, with acute primary (migraine, tension type and cluster) headache referred to the ED were included in this study. Pain severity was measured with 10 centimeters numeric rating scales. The patients were randomized into two groups of intravenous (IV) metoclopramide (10 milligrams) and acetaminophen (1 gram). Pain score, success rate, and drug complications were compared between the 2 groups at 0, 15, 30, 60, and 120 minutes after injection. </p></sec><sec><title>Results:</title><p> 100 patients were equally categorized into two groups (mean age of 32 &#x000b1; 13.2 years; 51.2% male). Initial pain score in metoclopramide and acetaminophen groups were 9.1 and 9.4, respectively (p = 0.46). IV metoclopramide did not have any analgesic effect at 15 minutes, but had good effect at 30 minutes. While, the analgesic effect of acetaminophen initiated after 15 minutes. After 2 hours, both drugs had good therapeutic effect on primary headaches (p &#x0003c; 0.001). </p></sec><sec><title>Conclusion:</title><p>The present study demonstrated that efficacy of metoclopramide for pain relief in primary headaches is lower than acetaminophen. In this regard, success rate of acetaminophen was 42.0% versus 0% for metoclopramide within 15 minutes. The efficacy of acetaminophen continued until 60 minutes.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Metoclopramide</kwd><kwd>acetaminophen</kwd><kwd>headache</kwd><kwd>migraine</kwd><kwd>acute pain</kwd></kwd-group></article-meta></front><body><sec><title>Introduction:</title><p>PHeadache is one of the most common neurologic symptoms among patients admitted to the emergency department (ED), as 3 million patients are annually visited only in the EDs of United States (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). The disease is categorized into primary (such as migraine, tension type, and cluster) and secondary (such as those following intracerebral hemorrhage, trauma, tumor, etc.) groups. Primary is the most frequent type seen in EDs and 90% of them include migraine, tension, or even a combination of them (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Approximately, 12% of general population suffer from migraine and acute exacerbations cause severe and disabling disorders (<xref rid="B5" ref-type="bibr">5</xref>-<xref rid="B7" ref-type="bibr">7</xref>). Several agents such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antiemetics, antipsychotics, etc. have been used for treatment (<xref rid="B8" ref-type="bibr">8</xref>). Recently, the use of dopamine antagonists, such as metoclopramide (alone or in combination with other drugs), and serotonin agonists, like sumatriptan, for this purpose has increased (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Administration of metoclopramide relieves the intensity of headaches; however, its efficacy varies among studies. For example, while, Tec et al. declared an acceptable therapeutic effect for metoclopramide in primary headaches, Coppola et al. deemed its efficacy to be equal to placebo (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). Given the above results, evaluation of metoclopramide&#x02019;s efficacy in management of primary headaches requires more studies to derive a concrete and clear conclusion. Therefore, the present study aimed to compare analgesic effects of intravenous (IV) metoclopramide and acetaminophen for acute primary headaches.</p></sec><sec><title>Methods:</title><p>
<bold><italic>Study design and setting</italic></bold>
</p><p>This study was a double-blind randomized clinical trial performed in Imam Khomeini Hospital, Urmia, Iran, through July to October 2014. The effect of IV metoclopramide (10 milligrams) and acetaminophen (1 gram) in treatment of acute headaches was compared. For ethical reasons, there was no placebo arm. The study protocol was confirmed by Ethical Committee of Urmia University of Medical Sciences and informed consent was obtained from patients. This protocol was registered in Iranian Registry of Clinical Trials with IRCT Number: IRCT2014081817812N3.</p><p>
<bold><italic>Subjects</italic></bold>
</p><p>Patients with acute primary headache and pain severity over 4 based on numeric rating scale (NRS), who were referred to the ED and did not have any systematic disease, were included. Exclusion criteria were having allergy to metoclopramide and acetaminophen, hepatic failure, secondary headache, pregnancy, breast-feeding, renal insufficiency, arbitrary treatment, and the case of recurrent headache. Migraine, tension type, and cluster headaches were diagnosed based on International Headache Society&#x02019;s International Classification of Headache Disorders (ICHD) criteria (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>
<bold><italic>Intervention</italic></bold>
</p><p>The patients were randomized into two groups of metoclopramide (intervention group) with dosage of 10 milligrams, IV, in 2 minutes and acetaminophen group (control group) with dosage of 1 gram, slow IV, in 10 minutes. Randomization was performed by block randomization (size of 5 for blocks), using an online random number generator (RNG). Solutions were prepared by an independent pharmacist and kept in a sealed envelope. Drugs were injected by a physician blinded to the studied groups. Response to treatment and the side effects were assessed within 15, 30, 60, and 120 minutes after receiving medications and then compared with the baseline. The ED staff were blinded to composition of solutions and studied groups. The data of the prescribed solution were only available for the staff when drug complications and other adverse effects appeared in patients and the patient was excluded from the study. Rescue dose was prescribed, if the pain continued after 30 minutes from first drug administration. The disclosure of the data about the prescribed medicine(s) was not required during the study period. </p><p>
<bold><italic>Measurements</italic></bold>
</p><p>11-scale standard numeric rating scale (NRS) was used to assess the pain score of patients (<xref rid="B14" ref-type="bibr">14</xref>). Patients were given a score number between 0 and 10, 0 representing no pain and 10 demonstrating the worst conceivable pain. Pain severity was assessed in the baseline (administration time) and then reassessed 15, 30, 60, and 120 minutes after medication. This follow up was performed because 120 minutes is a more standard endpoint for outpatient migraine trials (<xref rid="B15" ref-type="bibr">15</xref>). Nausea, vomiting, vertigo, and lethargy were recorded as adverse effects based on self-reports and clinical manifestations. Therapeutic success rate was defined as decreasing pain score to at least 3. </p><p>
<bold><italic>Statistical analysis </italic></bold>
</p><p>The minimum required sample size for the present study considering the clinically significant change of 2 scores in pain severity, standard deviation of 2.7 and 1.2 centimeters for effects of metoclopramide and acetaminophen in decreasing headache, power of 90% (&#x003b2;=0.1) and the error rate of 5% (&#x003b1;=0.05) was estimated to be 33 subjects (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). </p><p>Data were analyzed using SPSS 21. Quantitative variables were reported as mean and standard deviation and qualitative ones as frequency and percentage. Chi-square and Fisher exact tests were also used for comparison of basic characteristics of the two groups. Because data was not normally distributed, the comparison between pain severity changes in patients was performed using Wilcoxon-rank test. The success rate was reported as frequency and percentage as well as comparison of time changes between two therapies performed by non-parametric test for trend, which is an extension model of the Wilcoxon rank-sum test. Since some basic features between two therapeutic groups had significant difference, general linear model was done to find if success rate had significant difference after moderating these factors. P &#x0003c; 0.05 was considered as a significant level.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparison of demographic data between two studied groups</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Variable</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Acetaminophen</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Metoclopramide</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>p</bold>
<xref ref-type="table-fn" rid="TFN1">1</xref>
</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Age (year)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x0003c;18</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (43.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (56.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;18-40</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (67.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (32.8)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;41-60</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (100.0)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;61-75</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (100.0)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (51.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (48.8)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (49.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (50.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Marital status </bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Single</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (53.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (46.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Married</td><td align="center" valign="middle" rowspan="1" colspan="1">35 (48.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (51.4)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" colspan="2" rowspan="1">
<bold>Type of headache</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Migraine</td><td align="center" valign="middle" rowspan="1" colspan="1">35 (67.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (32.7)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Tension type</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (23.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (76.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Cluster</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>1</label><p>, Based on Chi-Squared test; </p></fn><fn id="TFN2"><label>2</label><p>, based on Fisher exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>comparison of pain score and successes rate in medical interventions between studied groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="2" colspan="1">
<bold>Time (minute)</bold>
</th><th align="center" valign="middle" colspan="2" rowspan="1">
<bold>Acetaminophen</bold>
<hr/>
</th><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" colspan="2" rowspan="1">
<bold>Metoclopramide</bold>
<hr/>
</th><th align="center" valign="middle" rowspan="2" colspan="1">
<bold>p</bold>
<xref ref-type="table-fn" rid="TFN3">1</xref>
</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SD</th><th align="center" valign="middle" rowspan="1" colspan="1">Success rate (%)</th><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SD</th><th align="center" valign="middle" rowspan="1" colspan="1">Success rate (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Baseline</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">9.4 &#x000b1; 0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">----</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">9.1 &#x000b1; 1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">----</td><td align="center" valign="middle" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold> 15</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7.0 &#x000b1; 1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (42.0)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">9.0 &#x000b1; 1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>30</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5 &#x000b1; 2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (100.0)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">6.6 &#x000b1; 1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (74.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>60</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1 &#x000b1; 2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (100.0)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">5.4 &#x000b1; 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">47 (94.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>120</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 &#x000b1; 1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (100.0)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">3.6 &#x000b1; 2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (100.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>1</label><p>, Based on Kruskal-Wallis equality of populations rank test; SD: Standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>results of multivariate analysis for comparison of success rate between two groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Time (minute)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Odds ratio</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>p</bold>
<xref ref-type="table-fn" rid="TFN4">1</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>15</bold>
</td><td align="center" rowspan="1" colspan="1">1.43</td><td align="center" rowspan="1" colspan="1">1.21-1.73</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>30</bold>
</td><td align="center" rowspan="1" colspan="1">1.38</td><td align="center" rowspan="1" colspan="1">1.17-1.64</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>60</bold>
</td><td align="center" rowspan="1" colspan="1">1.10</td><td align="center" rowspan="1" colspan="1">1.01-1.26</td><td align="center" rowspan="1" colspan="1">0.04</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><label>1</label><p>, Based on general linear model adjusted for age and type of headache; CI: Confidence interval.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Results:</title><p> 100 patients were equally categorized into two groups of IV acetaminophen and metoclopramide (mean age of 32 &#x000b1; 13.2 years; 51.2% male). <xref ref-type="table" rid="T1">Table 1</xref> shows demographic data of patients. As can be seen, age distribution of the two groups was significantly different (p &#x0003c; 0.001). Most migraine sufferers received IV acetaminophen, while patients with tension headache mostly took metoclopramide (<xref ref-type="table" rid="T1">Table 1</xref>, p &#x0003c; 0.001). The pain severity at administration time had no difference between the groups (p = 0.46). However, the mean pain severity at 15 minutes after taking acetaminophen was significantly less than metoclopramide group (7.0 &#x000b1; 1.4 versus 9.0 &#x000b1; 1.3, p &#x0003c; 0.001). This pattern was seen within 30 minutes (4.5 &#x000b1; 2.0 versus 6.6 &#x000b1; 1.5; p &#x0003c; 0.001), 60 minutes (3.1 &#x000b1; 2.1 versus 5.4 &#x000b1; 1.6; p &#x0003c; 0.001), and even 120 minutes (3.6 &#x000b1; 2.0 versus 1.5 &#x000b1; 1.2; p &#x0003c; 0.001) after injection (<xref ref-type="table" rid="T2">Table 2</xref>). </p><p>21 (42%) patients in acetaminophen group had significant pain relief, while none of subjects in metoclopramide group had such effectiveness in 15 minutes after medication. The 30-minute success rate for acetaminophen and metoclopramide groups were 100% and 74%, respectively. 100% therapeutic success rate in IV acetaminophen remained until 120 minutes (<xref ref-type="table" rid="T2">Table 2</xref>, p = 0.001). No side effect was seen among patients. Only 3 (6%) patients of metoclopramide group needed the rescue dose. After adjustment of analysis for basic characteristics, the rate of therapeutic success for IV acetaminophen at 15 minutes (OR=1.43; 95% Cl=1.2-1.7; p &#x0003c; 0.001), 30 minutes (OR=1.38; 95%Cl=1.17-1.64; p &#x0003c; 0.001), and 60 minutes (OR=1.10; 95% Cl=1.01-1.26; p = 0.04) was more than metoclopramide (<xref ref-type="table" rid="T3">Table 3</xref>).</p></sec><sec><title>Discussion:</title><p>Based on the present study and similar to other major studies, metoclopramide had a pain relief effect on primary headaches, but in contrast to other researches, here metoclopramide had inferior effect to acetaminophen. It can be justified under racial differences. Several studies have been performed regarding therapeutic effects of metoclopramide on the primary headaches with different results. While some of them showed good efficacy of metoclopramide for primary headaches, others concluded no efficacy. Salazar-Z&#x000fa;&#x000f1;iga and Garfias-Arvizu compared metoclopramide and sumatriptan in migraine sufferers and demonstrated that metoclopramide is more effective (<xref rid="B18" ref-type="bibr">18</xref>). Tec et al. showed that metoclopramide has therapeutic effects on headache, alone (<xref rid="B4" ref-type="bibr">4</xref>). Coppola et al. compared prochlorperazine, metoclopramide, and placebo; they showed that prochlorperazine has therapeutic effects on headache, but metoclopramide is more effective than placebo (<xref rid="B9" ref-type="bibr">9</xref>). In contrast, Cameron et al. compared prochlorperazine and metoclopramide, and demonstrated that prochlorperazine and metoclopramide are both effective on acute migraine headaches (<xref rid="B19" ref-type="bibr">19</xref>). Colman et al. concluded that metoclopramide is effective on the migraine especially in combination with other agents (<xref rid="B20" ref-type="bibr">20</xref>). Friedman et al. stated that a combination of metoclopramide and diphenhydramine are more effective than ketorolac for headaches (<xref rid="B21" ref-type="bibr">21</xref>). In another study, Friedman et al. compared 10 milligrams of IV prochlorperazine and combination of 20 milligrams metoclopramide and 25 milligrams diphenhydramine for acute migraine headaches. They showed prochlorperazine and combination of metoclopramide and diphenhydramine have the same effect for acute migraine headaches (<xref rid="B22" ref-type="bibr">22</xref>). In another study, Friedman et al. displayed 10 metoclopramide are more efficient than 30 milligrams ketorolac or 1000 milligrams valproate sodium (<xref rid="B23" ref-type="bibr">23</xref>). Weinman et al. performed a systemic review to find an effective drug for tension type of headaches and reviewed 8 studies. Their results were as below: metamizole, chlorpromazine, and metoclopramide are more effective than placebo for acute pain. The combination of metoclopramide with diphenhydramine has superiority to ketorolac. mepivacaine, meperidine with promethazine, and sumatriptan are not more effective than placebo (<xref rid="B24" ref-type="bibr">24</xref>). The results of this study had some similarities and dissimilarities with other studies. Variances in regimens and doses of medications can result in different efficacy of medications, so that use of one standard regimen may lead to results that are more coherent. Extrapyramidal reactions are one of the most important side effects of metoclopramide, which have been reported in nearly 10% of cases. For example, Coppola et al. demonstrated 2.5% of patients displayed dystonia or akathisia in initial minutes of drug administration (<xref rid="B12" ref-type="bibr">12</xref>). Also Friedman et al. stated that akathisia developed in 9.3% of patients (<xref rid="B25" ref-type="bibr">25</xref>). However, no side effect was found in the present study. There were several limitations in this study. The first limitation was the short follow-up period. Although, during 2 hours follow up no side effect was observed, the longer period such as 1or 2 days and even 1week follow up might have provided a better opportunity to evaluate long-term side effects and headache recurrence. Another limitation was single-blinded design of the trial. We were unable to do the study in a double-blinded way, because the routes of administration for drugs were different. Moreover, the lack of a placebo group or standard arm due to ethical consideration was also considered as another limitation.</p></sec><sec><title>Conclusion:</title><p>The present study demonstrated that efficacy of metoclopramide in pain relief of headaches is lower than acetaminophen. In this regard, success rate of acetaminophen in pain relief was 42.0%, while it was 0% for metoclopramide within 15 minutes. The efficacy of acetaminophen continued until 60 minutes.</p></sec></body><back><ack><title>Acknowledgments:</title><p>All authors would like to say thanks to all staff of Imam Khomeini Hospital and the research center of Urmia University of Medical Sciences. </p></ack><sec><title>Conflict of interest:</title><p>None</p></sec><sec><title>Funding support:</title><p>This study was granted by the research center of Urmia University of Medical Sciences, grant number: 1872143-25</p></sec><sec><title>Authors&#x02019; contributions:</title><p>All authors passed four criteria for authorship contribution based on recommendations of the International Committee of Medical Journal Editors.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>FR</given-names></name></person-group><article-title>Diagnosis and classification of headache</article-title><source> Prim Care</source><year>2004</year><volume>31</volume><issue>2</issue><fpage>243</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">15172505</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McCaig</surname><given-names>LF</given-names></name><name><surname>Nawar</surname><given-names>EW</given-names></name></person-group><article-title>National hospital ambulatory medical care survey: 2004 emergency department summary</article-title><year>2006</year><publisher-name>US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics</publisher-name><comment>372</comment></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>BW</given-names></name><name><surname>Hochberg</surname><given-names>ML</given-names></name><name><surname>Esses</surname><given-names>D</given-names></name><etal/></person-group><article-title>Applying the International Classification of Headache Disorders to the emergency department: an assessment of reproducibility and the frequency with which a unique diagnosis can be assigned to every acute headache presentation</article-title><source> Ann Emerg Med</source><year>2007</year><volume>49</volume><issue>4</issue><fpage>409</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">17210203</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tek</surname><given-names>DS</given-names></name><name><surname>McClellan</surname><given-names>DS</given-names></name><name><surname>Olshaker</surname><given-names>JS</given-names></name><name><surname>Allen</surname><given-names>CL</given-names></name><name><surname>Arthur</surname><given-names>DC</given-names></name></person-group><article-title>A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department</article-title><source> Ann Emerg Med</source><year>1990</year><volume>19</volume><issue>10</issue><fpage>1083</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2221512</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>S</given-names></name><name><surname>Bigal</surname><given-names>ME</given-names></name><name><surname>Silberstein</surname><given-names>S</given-names></name><name><surname>Loder</surname><given-names>E</given-names></name><name><surname>Reed</surname><given-names>M</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group><article-title>Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study</article-title><source> Headache</source><year>2007</year><volume>47</volume><issue>3</issue><fpage>355</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">17371352</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name></person-group><article-title>Migraine&#x02014;current understanding and treatment</article-title><source> N Engl J Med</source><year>2002</year><volume>346</volume><issue>4</issue><fpage>257</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">11807151</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>AJ</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name></person-group><article-title>Migraine&#x02014;Current Understanding and Treatment</article-title><source> N Engl J Med</source><year>2002</year><volume>346</volume><issue>4</issue><fpage>257</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">11807151</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinson</surname><given-names>DR</given-names></name></person-group><article-title>Treatment patterns of isolated benign headache in US emergency departments</article-title><source> Ann Emerg Med</source><year>2002</year><volume>39</volume><issue>3</issue><fpage>215</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11867972</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppola</surname><given-names>M</given-names></name><name><surname>Yealy</surname><given-names>DM</given-names></name><name><surname>Leibold</surname><given-names>RA</given-names></name></person-group><article-title>Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache</article-title><source> Ann Emerg Med</source><year>1995</year><volume>26</volume><issue>5</issue><fpage>541</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7486359</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talabi</surname><given-names>S</given-names></name><name><surname>Masoumi</surname><given-names>B</given-names></name><name><surname>Azizkhani</surname><given-names>R</given-names></name><name><surname>Esmailian</surname><given-names>M</given-names></name></person-group><article-title>Metoclopramide versus sumatriptan for treatment of migraine headache: A randomized clinical trial</article-title><source> J Res Med Sci</source><year>2013</year><volume>18</volume><issue>8</issue><lpage>695</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashina</surname><given-names>S</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name></person-group><article-title>Intravenous treatment of migraine</article-title><source> Tech Reg Anesth Pain Manag</source><year>2012</year><volume>16</volume><issue>1</issue><fpage>25</fpage><lpage>9</lpage></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppola</surname><given-names>M</given-names></name><name><surname>Yealy</surname><given-names>DM</given-names></name><name><surname>Leibold</surname><given-names>RA</given-names></name></person-group><article-title>Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache</article-title><source> Annals of emergency medicine</source><year>1995</year><volume>26</volume><issue>5</issue><fpage>541</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7486359</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Steiner</surname><given-names>T</given-names></name></person-group><article-title>The International classification of headache disorders, 2nd edn (ICDH-II)</article-title><source> J Neurol Neurosurg Psychiatry</source><year>2004</year><volume>75</volume><issue>6</issue><fpage>808</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">15145989</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>KH</given-names></name><name><surname>Funk</surname><given-names>KG</given-names></name><name><surname>Funk</surname><given-names>JP</given-names></name><name><surname>Bonacci</surname><given-names>R</given-names></name></person-group><article-title>Clinical significance of reported changes in pain severity</article-title><source> Ann Emerg Med</source><year>1996</year><volume>27</volume><issue>4</issue><fpage>485</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8604867</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tfelt&#x02010;Hansen</surname><given-names>P</given-names></name><name><surname>Block</surname><given-names>G</given-names></name><name><surname>Dahl&#x000f6;f</surname><given-names>C</given-names></name><etal/></person-group><article-title>Guidelines for controlled trials of drugs in migraine</article-title><source> Cephalalgia</source><year>2000</year><volume>20</volume><issue>9</issue><fpage>765</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">11167908</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkcuer</surname><given-names>I</given-names></name><name><surname>Serinken</surname><given-names>M</given-names></name><name><surname>Eken</surname><given-names>C</given-names></name><etal/></person-group><article-title>Intravenous paracetamol versus dexketoprofen in acute migraine attack in the emergency department: a randomised clinical trial</article-title><source> Emerg Med J</source><volume>2014</volume><fpage>182</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">24394884</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colman</surname><given-names>I</given-names></name><name><surname>Friedman</surname><given-names>BW</given-names></name><name><surname>Brown</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence</article-title><source> BMJ</source><year>2008</year><volume>336</volume><issue>7657</issue><fpage>1359</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">18541610</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar-Z&#x000fa;&#x000f1;ig</surname><given-names>A</given-names></name><name><surname>Garfias-Arvizu</surname><given-names>A</given-names></name></person-group><article-title>Management of the acute migraine episode with sumatriptan vs. metoclopramide</article-title><source> Rev Biomed</source><year>2006</year><volume>17</volume><fpage>175</fpage><lpage>82</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>JD</given-names></name><name><surname>Lane</surname><given-names>PL</given-names></name><name><surname>Speechley</surname><given-names>M</given-names></name></person-group><article-title>Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache</article-title><source> Acad Emerg Med</source><year>1995</year><volume>2</volume><issue>7</issue><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">8521205</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colman</surname><given-names>I</given-names></name><name><surname>Brown</surname><given-names>MD</given-names></name><name><surname>Innes</surname><given-names>GD</given-names></name><name><surname>Grafstein</surname><given-names>E</given-names></name><name><surname>Roberts</surname><given-names>TE</given-names></name><name><surname>Rowe</surname><given-names>BH</given-names></name></person-group><article-title>Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials</article-title><source> BMJ</source><year>2004</year><volume>329</volume><issue>7479</issue><fpage>1369</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15550401</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>BW</given-names></name><name><surname>Adewunmi</surname><given-names>V</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name><etal/></person-group><article-title>A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches</article-title><source> Ann Emerg Med</source><year>2013</year><volume>62</volume><issue>4</issue><fpage>311</fpage><lpage>8</lpage><comment>e4</comment><pub-id pub-id-type="pmid">23567060</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>BW</given-names></name><name><surname>Esses</surname><given-names>D</given-names></name><name><surname>Solorzano</surname><given-names>C</given-names></name><etal/></person-group><article-title>A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine</article-title><source> Ann Emerg Med</source><year>2008</year><volume>52</volume><issue>4</issue><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">18006188</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>BW</given-names></name><name><surname>Garber</surname><given-names>L</given-names></name><name><surname>Yoon</surname><given-names>A</given-names></name><etal/></person-group><article-title>Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine</article-title><source> Neurology</source><year>2014</year><volume>82</volume><issue>11</issue><fpage>976</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">24523483</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinman</surname><given-names>D</given-names></name><name><surname>Nicastro</surname><given-names>O</given-names></name><name><surname>Akala</surname><given-names>O</given-names></name><name><surname>Friedman</surname><given-names>BW</given-names></name></person-group><article-title>Parenteral treatment of episodic tension-type headache: a systematic review</article-title><source> Headache</source><year>2014</year><volume>54</volume><issue>2</issue><fpage>260</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24433525</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>BW</given-names></name><name><surname>Mulvey</surname><given-names>L</given-names></name><name><surname>Esses</surname><given-names>D</given-names></name><etal/></person-group><article-title>Metoclopramide for acute migraine: a dose-finding randomized clinical trial</article-title><source> Ann Emerg Med</source><year>2011</year><volume>57</volume><issue>5</issue><fpage>475</fpage><lpage>82</lpage><comment>e1</comment><pub-id pub-id-type="pmid">21227540</pub-id></element-citation></ref></ref-list></back></article>